Informatore Specialist Rare Diseases-Lombardia
Pubblicato il 04-10-2026 - IQVIA Italia in Lombardia
On behalf of Alnylam, a leading biopharmaceutical company, pioneer in RNA interference (RNAi) therapies, with a highly specialized pipeline in rare genetic diseases, IQVIA, a global leader in services for the pharmaceutical and biotechnology industries, is seeking a Product Specialist Rare Diseases.
Working Area
Northern Italy (Lombardy, Piedmont, Liguria, Emilia‑Romagna and Tuscany);
Residence
Field‑based in Lombardy or Emilia Romagna;
Travel
Ability to travel within a territory on a regular basis (80% of the time).
Make a Meaningful Impact in Rare Diseases – Join Alnylam as Product Specialist, Rare Diseases.
Are you a driven and experienced professional with a passion for transforming patients’ lives? At Alnylam, we’re changing the future of medicine through our revolutionary RNAi technology — and we’re looking for exceptional talent to join us on this journey.
We have an exciting opportunity for a Product Specialist to join our dynamic commercial team in Italy with a focus on the Regions of Northern Italy.
In this field‑based role,
you will play a critical part in supporting healthcare professionals (HCPs) to identify and manage patients with acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1) — rare and often misdiagnosed conditions.
Reporting directly to the Field Business Lead Italy for the assigned region, the Product Specialist will manage and maintain relationships with nephrology, urology, ER specialists, as well as internal medicine physicians within the territory, and will collaborate closely with colleagues to ensure the achievement of set objectives.
The Product Specialist Rare Diseases (she/he) – is responsible for the strategic development and operational excellence of assigned products, serving as a scientific and commercial point of reference for internal and external stakeholders.
Promoting innovative therapeutic solutions for rare genetic diseases such as acute hepatic porphyria (AHP) and primary hyperoxaluria type 1